Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3302 - An individualized-approach to second-line systemic anti-cancer therapy for glioblastoma


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Central Nervous System Malignancies


Pinelopi Gkogkou


Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366


P. Gkogkou1, K.(. Geropantas1, T. Ajithkumar2

Author affiliations

  • 1 Oncology Department, Norfolk and Norwich University Hospital, NR4 7UY - Norwich/GB
  • 2 Oncology Department, Cambridge University Hospitals NHS Foundation Trust, CB2 0QQ - Cambridge/GB


Abstract 3302


The optimal second-line systemic anti-cancer therapy (SACT) for recurrent inoperable glioblastoma (GBM) is not known. Generally, patients with a recurrence within 6 months of adjuvant temozolomide (TMZ) are treated with procarbazine/lomustine/vincristine (PCV) regimen and those with a recurrence at least 6 months after completion of TMZ are re-challenged with TMZ (rTMZ). The aim of this study is to evaluate the clinical outcomes of this individualized approach.


We treated 46 patients with second-line SACT for recurrent GB between 2009 and 2015. The Response Assessment in Neuro-Oncology (RANO) criteria were used to assess treatment response. The Kaplan-Meier method was used to calculate survival. Patient- and disease-related characteristics between the groups were compared using the Fisher exact test.


31 patients received PCV and 15 patients received rTMZ (Table). The median progression-free (PFS) (3.4 months each) and overall survival (OS) (5.2 months vs. 5.3 months p = 0.482) from the start of second-line SACT were similar for both groups. Compared with the PCV group, the median PFS (19.6 months vs. 8.7 months, p = 0.001) and OS (28 months vs. 13.7 months, p = 0.001) calculated from the date of diagnosis were better for the rTMZ group. Toxicity was acceptable in both treatment groups.Table:


PCVTMZp value
Median age (years)57 (range 29-71)63 (range 34-80)0.119
Radiological Appearacne0.182
Adjuvant Treatment0.816
Radical chemo-RT25(80.6%)13(86.7%)
Radical RT alone2(6.5%)1(6.7%)
Palliative RT4(12.9%)1(6.7%)
Adjuvant treatment completed within 6 months1 (3%)11 (73%)0.001
Median time to progression after first-line (months)1.2 (range: 0.7-11.03)9.8 (range: 1-24.3)0.001


As the individualized approach of second-line SACT in recurrent GB leads to similar survival. Patients who recur more than 6 months after completion of primary chemo-radiotherapy generally have a better survival.

Clinical trial identification

Legal entity responsible for the study

Department of Radiation Oncology, Norfolk & Norwich University NHS Foundation Trust




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.